How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency
Tuesday October 7, 2025; 10am ET, 3pm BST, 4pm CET
Discover how Volv Global, in collaboration with Takeda, Cleveland Clinic, and Komodo, used AI to rapidly identify undiagnosed AATD patients, supporting earlier, more equitable, and personalized interventions and outcomes.
Artificial intelligence (AI) can uncover patterns in electronic health records that may be difficult to detect through traditional clinical review. By doing so, this supports earlier identification of patients with difficult-to-diagnose diseases, provides insights into disease progression, and helps guide the selection of the most appropriate treatment for each patient.
In this webinar, we will explore how AI is transforming patient diagnosis and treatment, using alpha-1 antitrypsin deficiency (AATD), a rare and often difficult-to-diagnose genetic condition, as a real-world example. The session will showcase how a collaboration between Takeda, Cleveland Clinic, Komodo, and Volv Global applied AI-driven insights from real-world data to achieve meaningful improvements in the patient journey.
What will you learn?
- AI Can Identify Undiagnosed Patients Earlier Than Ever Before
Discover how Volv Global’s machine learning model accurately flagged more than 16,000 previously undiagnosed AATD patients from a large, diverse patient database, demonstrating the model’s precision and reliability in a real-world scenario.
- AI Helps to Overcome Clinical Bias and Demographic Disparities
Learn how this AI-driven approach identified a significantly higher proportion of likely undiagnosed AATD cases among underrepresented ethnic and racial populations compared to conventional methods, ensuring more equitable patient care and addressing diagnostic disparities in healthcare.
- Deep Collaboration, Not Just Technology, is the True Game-Changer
Hear from Takeda, Cleveland Clinic, and Komodo Health experts on the unique collaborative methodology behind the project. Volv Global’s flexible, co-creative approach goes beyond traditional, static solutions, resulting in meaningful improvements in patient outcomes.
- Real-World Data-Driven Insights Significantly Improve Clinical Outcomes
See how predictive analytics, validated by international clinical experts, stratify patient populations and enable earlier, tailored interventions at scale through the ongoing AATD project.
- Personalization and Precision in Decision-Making
Understand how Volv Global’s AI-driven insights not only identify patients but also provide detailed phenotyping and stratification, enabling healthcare providers and pharmaceutical teams to deliver personalized, targeted treatments, optimizing both therapeutic outcomes and healthcare resource use.
Of interest to: Pharma: clinical development; Pharma: medical affairs; Pharma: HEOR; Pharma: commercial; Healthcare providers
Speakers
Marie Sanchirico, PhD, MBA
Senior Medical Director, Takeda Pharmaceuticals
Marie Sanchirico, PhD, MBA is an immunologist and medical affairs leader with over 15 years of experience in evidence generation, launch excellence and market access. Marie is currently a Senior Medical Director at Takeda, supporting their flagship brand, Entyvio, and previously helped launch eight treatments with Sanofi Genzyme. Prior to joining industry, Marie worked in academia at UMASS Medical School and received her bachelor degree at Ithaca College, PhD from UMASS, Amherst and MBA with Boston University. Outside of work, Marie treasures time with her three daughters, family and friends, is a dedicated yogi and loves to travel.
James K Stoller, MD, MS
Chief of Education, Cleveland Clinic
Dr Stoller is Chief of Education at Cleveland Clinic. He holds the Jean Wall Bennett Chair in Emphysema Research and the Samson Global Leadership Academy Chair at Cleveland Clinic. He is a pulmonary/critical care physician in the Cleveland Clinic Integrated Hospital Institute. He serves as the Senior Associate Dean for Academic Affairs (Cleveland Clinic Lerner College of Medicine) in the Case Western Reserve University School of Medicine.
His clinical research has focused on chronic obstructive pulmonary disease, especially alpha-1 antitrypsin deficiency, and on strategies of care delivery, especially respiratory therapy. He has authored/edited 20 books (including 6 editions of Egan’s Fundamentals of Respiratory Care), over 386 peer-reviewed reports, 88 chapters and more than 125 abstracts, and serves on the editorial board for Respiratory Care and previously Clinical Pulmonary Medicine and Critical Care Medicine. He also serves as the Section Editor on COPD for UpToDate.
Vickram Tejwani
Assistant Professor of Medicine, CCLCM/CWRU School of Medicine, Cleveland Clinic
Vickram Tejwani, MD a physician-scientist with joint appointments in the Department of Pulmonary and Critical Care and the Department of Genome Sciences and Systems Biology at Cleveland Clinic. Clinically, he serves as a referral physician statewide and nationally for complex cases of asthma, COPD, and alpha-1 antitrypsin deficiency. His research focuses on translational investigational of these three diseases to better understand predictors of worse disease and treatable traits, for which he holds NIH and other Foundational grants. As a part of this, Dr Tejwani is highly interested in technology for both case finding and identifying individuals at high risk of disease progression.
Scott Bryant
AVP, Partnerships, Komodo Health
Scott Bryant brings over 20 years of experience in the life sciences industry, combining a passion for innovation with a proven track record of impact. He began his career at Novo Nordisk, where he was recognized as an award-winning representative, before transitioning into the data and technology space. For the past five years, Scott has been with Komodo Health, partnering closely with top consultancies to transform their vision and expertise into measurable results. Through deeply collaborative relationships, he helps organizations unlock the full potential of data to drive meaningful outcomes across healthcare and life sciences.
Vahid Esmaeili, PhD
Data Science & Digital Health Director, Volv Global
Vahid Esmaeili is the Data Science and Digital Health Director at Volv Global. He has extensive experience at the intersection of medical devices, AI-driven healthcare, and neuroscience. He combines scientific rigor, analytical thinking, and industry expertise to transform complex challenges into impactful, scalable solutions that improve patient outcomes. Passionate about leveraging technology to bridge science, innovation, and healthcare, Vahid leads initiatives that deliver meaningful improvements in the field. Born and raised in Iran, he holds an M.Sc. in Biomedical Engineering from Sharif University of Technology and a Ph.D. in Neuroscience from SISSA in Italy, and has led multidisciplinary research at EPFL in Switzerland.
With thanks to The Evidence Base.
